Rudolph Navari to Cost-Benefit Analysis
This is a "connection" page, showing publications Rudolph Navari has written about Cost-Benefit Analysis.
Connection Strength
0.154
-
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients. Support Care Cancer. 2021 Aug; 29(8):4269-4275.
Score: 0.154